Skip to main
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is a clinical-stage biotechnology company with a positive outlook, as shown by their promising clinical programs and market opportunities for their proprietary therapies targeting Tregs. Despite competition and risks in the biotech industry, Coya Therapeutics has strong partnerships and ongoing pipeline expansion strategies, backed by solid intellectual property and orphan drug designations. With a current valuation and 12-month price target of $14 per share based on future revenue projections, Coya Therapeutics has solid potential for growth, especially considering its recent publication reinforcing the therapeutic potential of its product COYA 302 for frontotemporal dementia.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company that is at risk of facing competition in the intense biotechnology and pharmaceutical industry. Their current product candidate pipeline shows potential, but with a lack of revenue and increasing cash burn, there is a strong likelihood that the company will need to raise additional capital in the future. Additionally, while initial clinical data supports efficacy and safety of their product, there is a risk that regulators may not approve it for the requested indications.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.